MedroxyPROGESTERone acetate injectable suspension, USP

Product Features:

• An estrogen-free contraceptive
• Offers effective and discreet pregnancy prevention that does not require daily action
• Requires re-injection every 3 months (13 weeks), or only 4 times a year, at a healthcare provider

Limitations of Use: The use of medroxyPROGESTERone acetate injectable suspension is not recommended as a long-term (ie, longer than 2 years) birth control method unless other options are considered inadequate.

Women who use medroxyPROGESTERone acetate injectable suspension may lose significant bone mineral density. Bone loss is greater with increasing duration of use and may not be completely reversible.

It is unknown if use of medroxyPROGESTERone acetate injectable suspension during adolescence or early adulthood, a critical period of bone accretion, will reduce peak bone mass and increase the risk for osteoporotic fracture in later life MedroxyPROGESTERone acetate injectable suspension is not recommended as a long-term (ie, longer than 2 years) birth control method unless other options are considered inadequate.

The most common adverse reactions seen in medroxyPROGESTERone acetate injectable suspension, USP (incidence >5%) include: menstrual irregularities (57% at 12 months, 32% at 24 months), abdominal pain/discomfort (11%), weight gain >10 lbs at 24 months (38%), dizziness (6%), headache (17%), nervousness (11%), decreased libido (6%).

MedroxyPROGESTERone acetate injectable suspension does not protect against HIV infection (AIDS) and other sexually transmitted diseases (STDs).